JNJ Q1 2026 Earnings Beat, Div Hike & Growth Thesis
Key Questions
What were Johnson & Johnson's Q1 2026 earnings highlights?
JNJ reported EPS of $2.70, beating estimates, with revenue of $24.1B up 9.9% year-over-year. The company provided FY26 guidance, with next estimates at $2.83 EPS and $25.04B revenue.
How has JNJ's dividend growth compared to peers?
JNJ delivered 5.7% dividend growth versus P&G's 2.4%, reinforcing its status as a defensive dividend king. It also offers a steady 0.6-0.7% buyback yield.
What analyst ratings and price targets followed JNJ's Q1 results?
Leerink upgraded the stock to Outperform with a $265 target, while other price targets range from $252 to $279. Institutional buying has been confirmed.
What are the key growth drivers for JNJ in 2026?
Oncology growth from assets like Carvykti offsets loss-of-exclusivity impacts, while MedTech and pipeline products such as Icotyde support expansion. Q2 earnings are scheduled for July 15.
How has JNJ stock performed recently?
Shares traded at $231.29, up 0.48%, with YTD gains near 12%. The company maintains a strong cash flow position that supports dividends and growth initiatives.
EPS $2.70 beat, rev $24.1B +9.9% YoY. Next est $2.83 EPS/$25.04B rev. FY26 guide set. Price at $231.29 (+0.48%), Leerink upgraded to Outperform $265, PT $252-279. Oncology growth offsets LOE. Steady 0.6-0.7% buyback yield. Institutional buying confirmed. Dividend growth 5.7% vs P&G's 2.4% reinforces defensive King status. Q2 earnings call July 15. Balanced analysis highlights pipeline (Icotyde, Carvykti) and MedTech growth.